Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study

O'Malley, DM; Neffa, M; Monk, BJ; Melkadze, T; Huang, M; Kryzhanivska, A; Bulat, I; Meniawy, TM; Bagameri, A; Wang, EW; Uribe, BDD; Hegg, R; Feliu, WO; Ancukiewicz, M; Lugowska, I

O'Malley, DM (通讯作者)，Ohio State Univ, 320 W 10th St, Columbus, OH 43210 USA.;O'Malley, DM (通讯作者)，James Comprehens Canc Ctr, 320 W 10th St, Columbus, OH 43210 USA.

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (7):

Abstract

PURPOSE Balstilimab (antiprogrammed death-1) and zalifrelimab (anticytotoxic T-lymphocyte-associated antigen-4) are two new checkpoint inhibitors emer......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索